Lumos Pharma Analysis
| LUMODelisted Stock | USD 4.34 0.01 0.23% |
Lumos Pharma is overvalued with Real Value of 3.54 and Hype Value of 4.34. The main objective of Lumos Pharma delisted stock analysis is to determine its intrinsic value, which is an estimate of what Lumos Pharma is worth, separate from its market price. There are two main types of Lumos Pharma's stock analysis: fundamental analysis and technical analysis.
The Lumos Pharma stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Lumos Pharma is usually not traded on Labour Day, Thanksgiving Day, Christmas Day, New Year 's Day, National Mourning Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day. Lumos Stock trading window is adjusted to America/New York timezone.
Lumos |
Lumos Stock Analysis Notes
About 33.0% of the company outstanding shares are owned by corporate insiders. The company recorded a loss per share of 4.28. Lumos Pharma last dividend was issued on the 19th of March 2020. The entity had 1:9 split on the 19th of March 2020. Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for rare diseases. Its lead therapeutic candidate LUM-201 is an oral growth hormone secretagogue ibutamoren, which is in Phase 2 clinical trial for the treatment of pediatric growth hormone deficiency and other rare endocrine disorders. Lumos Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 32 people. To find out more about Lumos Pharma contact Richard Hawkins at 512 215 2630 or learn more at https://lumos-pharma.com.Lumos Pharma Investment Alerts
| Lumos Pharma is not yet fully synchronised with the market data | |
| Lumos Pharma generated a negative expected return over the last 90 days | |
| Lumos Pharma has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 2.05 M. Net Loss for the year was (34.03 M) with profit before overhead, payroll, taxes, and interest of 1.52 M. | |
| Lumos Pharma currently holds about 79.51 M in cash with (31.09 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 9.49, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 33.0% of the company outstanding shares are owned by corporate insiders |
Lumos Pharma Upcoming and Recent Events
Earnings reports are used by Lumos Pharma to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period..
| 6th of March 2024 Upcoming Quarterly Report | View | |
| 1st of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 6th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Lumos Market Capitalization
The company currently falls under 'Micro-Cap' category with a current market capitalization of 37.54 M.Lumos Pharma Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Lumos Pharma insiders, such as employees or executives, is commonly permitted as long as it does not rely on Lumos Pharma's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Lumos Pharma insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Lumos Pharma Outstanding Bonds
Lumos Pharma issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Lumos Pharma uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Lumos bonds can be classified according to their maturity, which is the date when Lumos Pharma has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| US550241AA19 Corp BondUS550241AA19 | View |
Lumos Pharma Predictive Daily Indicators
Lumos Pharma intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Lumos Pharma stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
About Lumos Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Lumos Pharma prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Lumos shares will generate the highest return on investment. We also built our delisted stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Delisted Stock such as Lumos Pharma. By using and applying Lumos Stock analysis, traders can create a robust methodology for identifying Lumos entry and exit points for their positions.
Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for rare diseases. Its lead therapeutic candidate LUM-201 is an oral growth hormone secretagogue ibutamoren, which is in Phase 2 clinical trial for the treatment of pediatric growth hormone deficiency and other rare endocrine disorders. Lumos Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 32 people.
Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding Lumos Pharma to your portfolios without increasing risk or reducing expected return.Did you try this?
Run Portfolio Suggestion Now
Portfolio SuggestionGet suggestions outside of your existing asset allocation including your own model portfolios |
| All Next | Launch Module |
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.
Other Consideration for investing in Lumos Stock
If you are still planning to invest in Lumos Pharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Lumos Pharma's history and understand the potential risks before investing.
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Stocks Directory Find actively traded stocks across global markets | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio |